IL2 and sexually transmitted disease: All patients in the STI group resumed ART at the end of the long-term follow-up and 5 out of 6 in the IL-2 group (one patient did not need to resume ART during the 9 years following the final stop, keeping CD4 cells consistently between 600 and 1100 cells/μl and VL to range around log4).